Predictive cutoff point of admission N-terminal pro–B-type natriuretic peptide testing in the ED for prognosis of patients with acute heart failure

Abstract Objective The main objective of this study was to determine a cutoff level of plasma N-terminal pro–B-type natriuretic peptide (NT-proBNP) that could successfully predict the short- and long-term prognosis of patients with acute heart failure at the time of admission to the emergency depart...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of emergency medicine 2013-08, Vol.31 (8), p.1191-1195
Hauptverfasser: Golcuk, Yalcin, MD, Golcuk, Burcu, MD, Velibey, Yalcin, MD, Oray, Deniz, MD, Atilla, Ozge Duman, MD, Colak, Ayfer, MD, Kurtulmus, Yusuf, MD, Yıldırım, Aydın, MD, Eren, Mehmet, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1195
container_issue 8
container_start_page 1191
container_title The American journal of emergency medicine
container_volume 31
creator Golcuk, Yalcin, MD
Golcuk, Burcu, MD
Velibey, Yalcin, MD
Oray, Deniz, MD
Atilla, Ozge Duman, MD
Colak, Ayfer, MD
Kurtulmus, Yusuf, MD
Yıldırım, Aydın, MD
Eren, Mehmet, MD
description Abstract Objective The main objective of this study was to determine a cutoff level of plasma N-terminal pro–B-type natriuretic peptide (NT-proBNP) that could successfully predict the short- and long-term prognosis of patients with acute heart failure at the time of admission to the emergency department. The results of our study are presented in context with previously published literature. We believe that the present study will be useful and salutary for the progress of literature. Methods N-terminal pro–B-type natriuretic peptide plasma levels were obtained from 100 patients with shortness of breath and left ventricular dysfunction upon admission to the emergency department. All patients underwent follow-up evaluations 30 days and 1 year after admission. The end point was defined as all-cause mortality. Results The mean age of the patients in this study was 70.8 ± 11.6 years, and 51% were female. All-cause mortality at the 30-day and 1-year follow-up evaluations was 21.2% and 53.5%, respectively. We determined that the optimal NT-proBNP cutoff point for predicting 30-day mortality at the time of admission was 9152.4 pg/mL, with a 71.4% sensitivity and an 81.3% specificity (95% confidence interval, area under the curve: 0.726; P = .002). The optimal NT-proBNP cutoff point for predicting 1-year mortality at the time of admission was 3630.5 pg/mL, with an 83.0% sensitivity and a 52.2% specificity (95% confidence interval, area under the curve: 0.644; P = .014). Conclusion Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute heart failure at 30 days and 1 year after admission. Furthermore, the optimal cutoff level of NT-proBNP used to predict 30-day and 1-year mortality had high sensitivity.
doi_str_mv 10.1016/j.ajem.2013.04.038
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1418142978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0735675713002751</els_id><sourcerecordid>3031681741</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-a8126054f4451d2c3c27d1f107e489c815edf1701a44dc1857781fa1545dee223</originalsourceid><addsrcrecordid>eNp9ks1u1TAQhSMEopfCC7BAltiwSfA49nUiISQo5UeqAAlYW8YZ9zokcWo7RXfHOyBekCfB4RaQumDlzXeOZ86ZorgPtAIK28d9pXscK0ahriivaN3cKDYgalY2IOFmsaGyFuVWCnlU3ImxpxSAC367OGK1FO224Zvix_uAnTPJXSIxS_LWktm7KRFvie5GF6PzE3lbJgyjm_RA5uB_fvv-vEz7GcmkU3BLwOQMmXFOrkOSMCY3nRM3kbRDcvqCWB9W2fnko4ur8ayTwylF8tWlHdH5XyQ71CERq92Q_e4Wt6weIt67eo-LTy9PP568Ls_evXpz8uysNLxuU6kbYFsquOVcQMdMbZjswAKVyJvWNCCwsyApaM47A42QsgGrQXDRITJWHxePDr55vIslD67yxgaHQU_ol6iAQwOctbLJ6MNraO-XkBP5TQloc6IiU-xAmeBjDGjVHNyow14BVWtpqldraWotTVGucmlZ9ODKevk8YvdX8qelDDw5AJizuHQYVDQ5QJObC2iS6rz7v__Ta3IzuMkZPXzBPcZ_e6jIFFUf1rNZrwZqSpkUUP8CaE6_HA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1415197595</pqid></control><display><type>article</type><title>Predictive cutoff point of admission N-terminal pro–B-type natriuretic peptide testing in the ED for prognosis of patients with acute heart failure</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Golcuk, Yalcin, MD ; Golcuk, Burcu, MD ; Velibey, Yalcin, MD ; Oray, Deniz, MD ; Atilla, Ozge Duman, MD ; Colak, Ayfer, MD ; Kurtulmus, Yusuf, MD ; Yıldırım, Aydın, MD ; Eren, Mehmet, MD</creator><creatorcontrib>Golcuk, Yalcin, MD ; Golcuk, Burcu, MD ; Velibey, Yalcin, MD ; Oray, Deniz, MD ; Atilla, Ozge Duman, MD ; Colak, Ayfer, MD ; Kurtulmus, Yusuf, MD ; Yıldırım, Aydın, MD ; Eren, Mehmet, MD</creatorcontrib><description>Abstract Objective The main objective of this study was to determine a cutoff level of plasma N-terminal pro–B-type natriuretic peptide (NT-proBNP) that could successfully predict the short- and long-term prognosis of patients with acute heart failure at the time of admission to the emergency department. The results of our study are presented in context with previously published literature. We believe that the present study will be useful and salutary for the progress of literature. Methods N-terminal pro–B-type natriuretic peptide plasma levels were obtained from 100 patients with shortness of breath and left ventricular dysfunction upon admission to the emergency department. All patients underwent follow-up evaluations 30 days and 1 year after admission. The end point was defined as all-cause mortality. Results The mean age of the patients in this study was 70.8 ± 11.6 years, and 51% were female. All-cause mortality at the 30-day and 1-year follow-up evaluations was 21.2% and 53.5%, respectively. We determined that the optimal NT-proBNP cutoff point for predicting 30-day mortality at the time of admission was 9152.4 pg/mL, with a 71.4% sensitivity and an 81.3% specificity (95% confidence interval, area under the curve: 0.726; P = .002). The optimal NT-proBNP cutoff point for predicting 1-year mortality at the time of admission was 3630.5 pg/mL, with an 83.0% sensitivity and a 52.2% specificity (95% confidence interval, area under the curve: 0.644; P = .014). Conclusion Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute heart failure at 30 days and 1 year after admission. Furthermore, the optimal cutoff level of NT-proBNP used to predict 30-day and 1-year mortality had high sensitivity.</description><identifier>ISSN: 0735-6757</identifier><identifier>EISSN: 1532-8171</identifier><identifier>DOI: 10.1016/j.ajem.2013.04.038</identifier><identifier>PMID: 23759684</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute Disease ; Aged ; Angina pectoris ; Biomarkers - blood ; Cardiovascular disease ; Cross-Sectional Studies ; Electrocardiography ; Emergency ; Emergency medical care ; Emergency Service, Hospital ; Female ; Heart attacks ; Heart Failure - blood ; Heart Failure - diagnosis ; Heart Failure - mortality ; Humans ; Male ; Mortality ; Natriuretic Peptide, Brain - blood ; Peptide Fragments - blood ; Prognosis ; Prospective Studies ; Sensitivity and Specificity</subject><ispartof>The American journal of emergency medicine, 2013-08, Vol.31 (8), p.1191-1195</ispartof><rights>Elsevier Inc.</rights><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-a8126054f4451d2c3c27d1f107e489c815edf1701a44dc1857781fa1545dee223</citedby><cites>FETCH-LOGICAL-c439t-a8126054f4451d2c3c27d1f107e489c815edf1701a44dc1857781fa1545dee223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1415197595?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993,64383,64385,64387,72239</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23759684$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Golcuk, Yalcin, MD</creatorcontrib><creatorcontrib>Golcuk, Burcu, MD</creatorcontrib><creatorcontrib>Velibey, Yalcin, MD</creatorcontrib><creatorcontrib>Oray, Deniz, MD</creatorcontrib><creatorcontrib>Atilla, Ozge Duman, MD</creatorcontrib><creatorcontrib>Colak, Ayfer, MD</creatorcontrib><creatorcontrib>Kurtulmus, Yusuf, MD</creatorcontrib><creatorcontrib>Yıldırım, Aydın, MD</creatorcontrib><creatorcontrib>Eren, Mehmet, MD</creatorcontrib><title>Predictive cutoff point of admission N-terminal pro–B-type natriuretic peptide testing in the ED for prognosis of patients with acute heart failure</title><title>The American journal of emergency medicine</title><addtitle>Am J Emerg Med</addtitle><description>Abstract Objective The main objective of this study was to determine a cutoff level of plasma N-terminal pro–B-type natriuretic peptide (NT-proBNP) that could successfully predict the short- and long-term prognosis of patients with acute heart failure at the time of admission to the emergency department. The results of our study are presented in context with previously published literature. We believe that the present study will be useful and salutary for the progress of literature. Methods N-terminal pro–B-type natriuretic peptide plasma levels were obtained from 100 patients with shortness of breath and left ventricular dysfunction upon admission to the emergency department. All patients underwent follow-up evaluations 30 days and 1 year after admission. The end point was defined as all-cause mortality. Results The mean age of the patients in this study was 70.8 ± 11.6 years, and 51% were female. All-cause mortality at the 30-day and 1-year follow-up evaluations was 21.2% and 53.5%, respectively. We determined that the optimal NT-proBNP cutoff point for predicting 30-day mortality at the time of admission was 9152.4 pg/mL, with a 71.4% sensitivity and an 81.3% specificity (95% confidence interval, area under the curve: 0.726; P = .002). The optimal NT-proBNP cutoff point for predicting 1-year mortality at the time of admission was 3630.5 pg/mL, with an 83.0% sensitivity and a 52.2% specificity (95% confidence interval, area under the curve: 0.644; P = .014). Conclusion Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute heart failure at 30 days and 1 year after admission. Furthermore, the optimal cutoff level of NT-proBNP used to predict 30-day and 1-year mortality had high sensitivity.</description><subject>Acute Disease</subject><subject>Aged</subject><subject>Angina pectoris</subject><subject>Biomarkers - blood</subject><subject>Cardiovascular disease</subject><subject>Cross-Sectional Studies</subject><subject>Electrocardiography</subject><subject>Emergency</subject><subject>Emergency medical care</subject><subject>Emergency Service, Hospital</subject><subject>Female</subject><subject>Heart attacks</subject><subject>Heart Failure - blood</subject><subject>Heart Failure - diagnosis</subject><subject>Heart Failure - mortality</subject><subject>Humans</subject><subject>Male</subject><subject>Mortality</subject><subject>Natriuretic Peptide, Brain - blood</subject><subject>Peptide Fragments - blood</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Sensitivity and Specificity</subject><issn>0735-6757</issn><issn>1532-8171</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9ks1u1TAQhSMEopfCC7BAltiwSfA49nUiISQo5UeqAAlYW8YZ9zokcWo7RXfHOyBekCfB4RaQumDlzXeOZ86ZorgPtAIK28d9pXscK0ahriivaN3cKDYgalY2IOFmsaGyFuVWCnlU3ImxpxSAC367OGK1FO224Zvix_uAnTPJXSIxS_LWktm7KRFvie5GF6PzE3lbJgyjm_RA5uB_fvv-vEz7GcmkU3BLwOQMmXFOrkOSMCY3nRM3kbRDcvqCWB9W2fnko4ur8ayTwylF8tWlHdH5XyQ71CERq92Q_e4Wt6weIt67eo-LTy9PP568Ls_evXpz8uysNLxuU6kbYFsquOVcQMdMbZjswAKVyJvWNCCwsyApaM47A42QsgGrQXDRITJWHxePDr55vIslD67yxgaHQU_ol6iAQwOctbLJ6MNraO-XkBP5TQloc6IiU-xAmeBjDGjVHNyow14BVWtpqldraWotTVGucmlZ9ODKevk8YvdX8qelDDw5AJizuHQYVDQ5QJObC2iS6rz7v__Ta3IzuMkZPXzBPcZ_e6jIFFUf1rNZrwZqSpkUUP8CaE6_HA</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Golcuk, Yalcin, MD</creator><creator>Golcuk, Burcu, MD</creator><creator>Velibey, Yalcin, MD</creator><creator>Oray, Deniz, MD</creator><creator>Atilla, Ozge Duman, MD</creator><creator>Colak, Ayfer, MD</creator><creator>Kurtulmus, Yusuf, MD</creator><creator>Yıldırım, Aydın, MD</creator><creator>Eren, Mehmet, MD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130801</creationdate><title>Predictive cutoff point of admission N-terminal pro–B-type natriuretic peptide testing in the ED for prognosis of patients with acute heart failure</title><author>Golcuk, Yalcin, MD ; Golcuk, Burcu, MD ; Velibey, Yalcin, MD ; Oray, Deniz, MD ; Atilla, Ozge Duman, MD ; Colak, Ayfer, MD ; Kurtulmus, Yusuf, MD ; Yıldırım, Aydın, MD ; Eren, Mehmet, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-a8126054f4451d2c3c27d1f107e489c815edf1701a44dc1857781fa1545dee223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acute Disease</topic><topic>Aged</topic><topic>Angina pectoris</topic><topic>Biomarkers - blood</topic><topic>Cardiovascular disease</topic><topic>Cross-Sectional Studies</topic><topic>Electrocardiography</topic><topic>Emergency</topic><topic>Emergency medical care</topic><topic>Emergency Service, Hospital</topic><topic>Female</topic><topic>Heart attacks</topic><topic>Heart Failure - blood</topic><topic>Heart Failure - diagnosis</topic><topic>Heart Failure - mortality</topic><topic>Humans</topic><topic>Male</topic><topic>Mortality</topic><topic>Natriuretic Peptide, Brain - blood</topic><topic>Peptide Fragments - blood</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Golcuk, Yalcin, MD</creatorcontrib><creatorcontrib>Golcuk, Burcu, MD</creatorcontrib><creatorcontrib>Velibey, Yalcin, MD</creatorcontrib><creatorcontrib>Oray, Deniz, MD</creatorcontrib><creatorcontrib>Atilla, Ozge Duman, MD</creatorcontrib><creatorcontrib>Colak, Ayfer, MD</creatorcontrib><creatorcontrib>Kurtulmus, Yusuf, MD</creatorcontrib><creatorcontrib>Yıldırım, Aydın, MD</creatorcontrib><creatorcontrib>Eren, Mehmet, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of emergency medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Golcuk, Yalcin, MD</au><au>Golcuk, Burcu, MD</au><au>Velibey, Yalcin, MD</au><au>Oray, Deniz, MD</au><au>Atilla, Ozge Duman, MD</au><au>Colak, Ayfer, MD</au><au>Kurtulmus, Yusuf, MD</au><au>Yıldırım, Aydın, MD</au><au>Eren, Mehmet, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive cutoff point of admission N-terminal pro–B-type natriuretic peptide testing in the ED for prognosis of patients with acute heart failure</atitle><jtitle>The American journal of emergency medicine</jtitle><addtitle>Am J Emerg Med</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>31</volume><issue>8</issue><spage>1191</spage><epage>1195</epage><pages>1191-1195</pages><issn>0735-6757</issn><eissn>1532-8171</eissn><abstract>Abstract Objective The main objective of this study was to determine a cutoff level of plasma N-terminal pro–B-type natriuretic peptide (NT-proBNP) that could successfully predict the short- and long-term prognosis of patients with acute heart failure at the time of admission to the emergency department. The results of our study are presented in context with previously published literature. We believe that the present study will be useful and salutary for the progress of literature. Methods N-terminal pro–B-type natriuretic peptide plasma levels were obtained from 100 patients with shortness of breath and left ventricular dysfunction upon admission to the emergency department. All patients underwent follow-up evaluations 30 days and 1 year after admission. The end point was defined as all-cause mortality. Results The mean age of the patients in this study was 70.8 ± 11.6 years, and 51% were female. All-cause mortality at the 30-day and 1-year follow-up evaluations was 21.2% and 53.5%, respectively. We determined that the optimal NT-proBNP cutoff point for predicting 30-day mortality at the time of admission was 9152.4 pg/mL, with a 71.4% sensitivity and an 81.3% specificity (95% confidence interval, area under the curve: 0.726; P = .002). The optimal NT-proBNP cutoff point for predicting 1-year mortality at the time of admission was 3630.5 pg/mL, with an 83.0% sensitivity and a 52.2% specificity (95% confidence interval, area under the curve: 0.644; P = .014). Conclusion Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute heart failure at 30 days and 1 year after admission. Furthermore, the optimal cutoff level of NT-proBNP used to predict 30-day and 1-year mortality had high sensitivity.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23759684</pmid><doi>10.1016/j.ajem.2013.04.038</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0735-6757
ispartof The American journal of emergency medicine, 2013-08, Vol.31 (8), p.1191-1195
issn 0735-6757
1532-8171
language eng
recordid cdi_proquest_miscellaneous_1418142978
source MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland
subjects Acute Disease
Aged
Angina pectoris
Biomarkers - blood
Cardiovascular disease
Cross-Sectional Studies
Electrocardiography
Emergency
Emergency medical care
Emergency Service, Hospital
Female
Heart attacks
Heart Failure - blood
Heart Failure - diagnosis
Heart Failure - mortality
Humans
Male
Mortality
Natriuretic Peptide, Brain - blood
Peptide Fragments - blood
Prognosis
Prospective Studies
Sensitivity and Specificity
title Predictive cutoff point of admission N-terminal pro–B-type natriuretic peptide testing in the ED for prognosis of patients with acute heart failure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T07%3A40%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20cutoff%20point%20of%20admission%20N-terminal%20pro%E2%80%93B-type%20natriuretic%20peptide%20testing%20in%20the%20ED%20for%20prognosis%20of%20patients%20with%20acute%20heart%20failure&rft.jtitle=The%20American%20journal%20of%20emergency%20medicine&rft.au=Golcuk,%20Yalcin,%20MD&rft.date=2013-08-01&rft.volume=31&rft.issue=8&rft.spage=1191&rft.epage=1195&rft.pages=1191-1195&rft.issn=0735-6757&rft.eissn=1532-8171&rft_id=info:doi/10.1016/j.ajem.2013.04.038&rft_dat=%3Cproquest_cross%3E3031681741%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1415197595&rft_id=info:pmid/23759684&rft_els_id=S0735675713002751&rfr_iscdi=true